We came across a bullish thesis on Sarepta Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc.'s share was trading at $21.55 as of December 15th. SRPT’s trailing and forward P/E were 169.47 and 17.39 respectively according to Yahoo Finance. Pixabay/Public Domain Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development o ...

公司概况 - Regenxbio是一家专注于基因疗法的临床阶段生物制药公司 在纳斯达克上市 股票代码为RGNX [1] - 公司成立于2008年 核心技术是利用AAV载体递送治疗性基因 [1] - 基于该技术平台的获批药物数量正在不断增加 [1] 行业研究服务 - ELAM1为金融专业人士和投资者提供科学和临床专业知识 帮助应对医疗健康领域的复杂性 [1] - 该服务旨在弥合前沿科学与金融策略之间的鸿沟 [1] - 服务内容包括发现潜在价值 更精准评估风险 以及在生命科学领域做出更明智的投资决策 [1]